PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

December 10, 2019Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
December 2, 2019Promore Pharma’s rights issue completed
November 22, 2019Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue
November 22, 2019Promore Pharma AB (publ) Interim report January – September 2019

More Press Releases

Third quarter 2019

Promore Pharma AB (publ) published its Interim report for the third quarter on 22 November 2019.

Report

Read the report

Calendar

February 18, 2020Year-end report 2019
May 26, 2020Annual General Meeting 2020
May 26, 2020Interim report 1 January – 31 March 2020

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.